Durso

Intercept Appoints M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer

Retrieved on: 
Wednesday, June 9, 2021
Pharmasset, Chief Medical Officer, The Intercept, Durso, Journalism, Observation, Articles

Dr. Berrey brings a wealth of leadership experience in drug development and executive management to Intercept, and I am very pleased to welcome her to the team, said Jerry Durso, President and Chief Executive Officer of Intercept.

Key Points: 
  • Dr. Berrey brings a wealth of leadership experience in drug development and executive management to Intercept, and I am very pleased to welcome her to the team, said Jerry Durso, President and Chief Executive Officer of Intercept.
  • I would also like to thank Dr. Gail Cawkwell, our Senior Vice President of Medical Affairs, Safety & Pharmacovigilance, for her strong leadership over the last several months as she took on additional responsibilities as Acting Chief Medical Officer.
  • Dr. Berrey was most recently President and Chief Executive Officer at Chimerix and previously served as Chief Medical Officer at Pharmasset from 2007 to 2012, prior to its acquisition by Gilead.
  • I look forward to helping the Intercept R&D team continue to build on its strong legacy of clinical research in liver disease.

Intercept Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 6, 2021
XC2, Durso, Boeing 787 Dreamliner, Aircraft

So at this time we cannot reiterate our potential filing timing for this year and expect to provide an update in the third quarter of this year,\xe2\x80\x9d Durso continued.

Key Points: 
  • So at this time we cannot reiterate our potential filing timing for this year and expect to provide an update in the third quarter of this year,\xe2\x80\x9d Durso continued.
  • Intercept now has an open IND for the combination in the U.S.\nIntercept intends to initiate first-in-human work with INT-787 in 2021.\nWe recognized\xc2\xa0$81.7 million\xc2\xa0in total revenue in the first quarter of 2021, as compared to\xc2\xa0$72.7 million\xc2\xa0in total revenue in the prior year quarter.
  • Among other things, our management uses non-GAAP adjusted operating expenses to establish budgets and operational goals and to manage our business.
  • Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended\xc2\xa0December 31, 2020.\nFor more information about Intercept, please contact:\n'

Fertility Socials in Philadelphia, PA and Fredericksburg, VA Included in Shady Grove Fertility's (SGF) Nine Physician-Led Educational Events this December

Retrieved on: 
Monday, November 25, 2019
Magazines, Periodicals, Bonnier Group, Conceive, Fertility, Durso, Schedule, Tapa, Media in the United States

"Oftentimes, fearing the unknown prevents people from scheduling their initial consultation with a fertility specialist.

Key Points: 
  • "Oftentimes, fearing the unknown prevents people from scheduling their initial consultation with a fertility specialist.
  • Dr. Durso will be hosting a Fertility Social event on Wednesday, December 11 at Tapa Rio in Fredericksburg .
  • When a couple is struggling to conceive, it's important to be evaluated by a fertility specialist sooner rather than later.
  • https://www.shadygrovefertility.com/resources/educational-resources
    While all SGF in-person and online events are complimentary, interested parties must register to attend by visiting the SGF calendar of events .